Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

Clinical trial NCT07468071 · RECRUITING

Trial details

NCT number: NCT07468071
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer Advanced Solid Tumors Harboring the KRAS G12C Mutation

Start date: 2026-06-08
Primary completion: 2029-06-11
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.